Gloria Matthews, Ankasa Regenerative Technologies - Novel Regenerative Medicine | LSI USA '24

Ankasa is developing ART352-L as a novel regenerative medicine. ART352-L will enhance the osteogenic properties of patient derived stem cells used in reconstructive surgeries.

LSI Europe ‘24 is filling fast. Secure your spot today to join Medtech and Healthtech leaders.

September 16-20, 2024 The Ritz-Carlton - Sintra, Portugal Register arrow